Evicenter
P&T meetings

LB-102

Schizophrenia

Regulatory submission
Not announced
Launch
Not announced
Last updated
345 sources

Section 6 of 6

References

345 sources

  1. Abbas et al. (2009) (opens in a new tab)
  2. AbbVie emraclidine phase 2 results announcement (2024) (opens in a new tab)
  3. AbbVie Form 10-K (2026) (opens in a new tab)
  4. AbbVie VRAYLAR prescribing information (2022) (opens in a new tab)
  5. Acacia Pharma BARHEMSYS prescribing information (2020) (opens in a new tab)
  6. Acacia Pharma BARHEMSYS prescribing information (2022) (opens in a new tab)
  7. Aceituno et al. (2020) (opens in a new tab)
  8. Achtyes et al. (2018) (opens in a new tab)
  9. Addington et al. (2015) (opens in a new tab)
  10. Agid et al. (2013) (opens in a new tab)
  11. Albert and McCaig (2015) (opens in a new tab)
  12. Aleman et al. (2003) (opens in a new tab)
  13. Alkermes LYBALVI prescribing information (2021) (opens in a new tab)
  14. American Diabetes Association et al. (2004) (opens in a new tab)
  15. American Psychiatric Association guideline statement summary (2020) (opens in a new tab)
  16. American Psychiatric Association guideline statements and implementation (2020) (opens in a new tab)
  17. Anand et al. (2025) (opens in a new tab)
  18. Andreasen et al. (2005) (opens in a new tab)
  19. Ascher-Svanum et al. (2010a) (opens in a new tab)
  20. Ascher-Svanum et al. (2010b) (opens in a new tab)
  21. Ayano et al. (2019) (opens in a new tab)
  22. Bai et al. (2021) (opens in a new tab)
  23. Bareis et al. (2025) (opens in a new tab)
  24. Barnes et al. (2020) (opens in a new tab)
  25. Biernat et al. (2022) (opens in a new tab)
  26. Bighelli et al. (2018) (opens in a new tab)
  27. Biso et al. (2025) (opens in a new tab)
  28. Bobes et al. (2010) (opens in a new tab)
  29. Boehringer Ingelheim CONNEX topline results announcement (2025) (opens in a new tab)
  30. Briggs et al. (2008) (opens in a new tab)
  31. Bristol Myers Squibb ARISE topline announcement (2025) (opens in a new tab)
  32. Bristol Myers Squibb ARISE topline results announcement (2025) (opens in a new tab)
  33. Bristol Myers Squibb COBENFY prescribing information (2024) (opens in a new tab)
  34. Brooks (2026) (opens in a new tab)
  35. Brugger et al. (2020) (opens in a new tab)
  36. Cannon et al. (2002) (opens in a new tab)
  37. Cantor-Graae and Selten (2005) (opens in a new tab)
  38. Carbon et al. (2017) (opens in a new tab)
  39. Ceraso et al. (2020) (opens in a new tab)
  40. Charlson et al. (2018) (opens in a new tab)
  41. Citrome et al. (2022) (opens in a new tab)
  42. ClinicalTrials.gov NCT04187560 (opens in a new tab)
  43. ClinicalTrials.gov NCT04588129 (opens in a new tab)
  44. ClinicalTrials.gov NCT05169710 (opens in a new tab)
  45. ClinicalTrials.gov NCT06179108 (opens in a new tab)
  46. ClinicalTrials.gov NCT06179108 (opens in a new tab)
  47. ClinicalTrials.gov NCT07145918 (opens in a new tab)
  48. ClinicalTrials.gov NCT07363577 (opens in a new tab)
  49. ClinicalTrials.gov NCT07369154 (opens in a new tab)
  50. ClinicalTrials.gov NCT07494305 (opens in a new tab)
  51. Cloutier et al. (2016) (opens in a new tab)
  52. CLOZARIL prescribing information (2025) (opens in a new tab)
  53. CMS 2027 Adult Core Set (opens in a new tab)
  54. CMS Adult Core Set chart pack (2024) (opens in a new tab)
  55. Colorado General Assembly HB23-1130 (2023) (opens in a new tab)
  56. Constantino (2024) (opens in a new tab)
  57. Correll and Howes (2021) (opens in a new tab)
  58. Correll and Schooler (2020) (opens in a new tab)
  59. Correll et al. (2017) (opens in a new tab)
  60. Correll et al. (2020a) (opens in a new tab)
  61. Correll et al. (2020b) (opens in a new tab)
  62. Correll et al. (2022) (opens in a new tab)
  63. Correll et al. (2026) (opens in a new tab)
  64. Davies et al. (2020) (opens in a new tab)
  65. de Leon and Diaz (2005) (opens in a new tab)
  66. Demjaha et al. (2012) (opens in a new tab)
  67. Department of Veterans Affairs and Department of Defense (2023) (opens in a new tab)
  68. Di Forti et al. (2019) (opens in a new tab)
  69. DiBonaventura et al. (2012) (opens in a new tab)
  70. Dickerson et al. (2013) (opens in a new tab)
  71. Dieterich et al. (2017) (opens in a new tab)
  72. Doane et al. (2024) (opens in a new tab)
  73. Doshi et al. (2024) (opens in a new tab)
  74. Durgam et al. (2014) (opens in a new tab)
  75. Durgam et al. (2015) (opens in a new tab)
  76. Emsley et al. (2013) (opens in a new tab)
  77. Englisch and Zink (2026) (opens in a new tab)
  78. Eramo et al. (2024) (opens in a new tab)
  79. Eramo et al. (2025a) (opens in a new tab)
  80. Eramo et al. (2025b) (opens in a new tab)
  81. Eramo et al. (2026a) (opens in a new tab)
  82. Eramo et al. (2026b) (opens in a new tab)
  83. Etchecopar-Etchart et al. (2021) (opens in a new tab)
  84. European Medicines Agency (2012) (opens in a new tab)
  85. Evensen et al. (2016) (opens in a new tab)
  86. Fabiano et al. (2025) (opens in a new tab)
  87. Farde et al. (1992) (opens in a new tab)
  88. Farley et al. (2008) (opens in a new tab)
  89. Fazel and Seewald (2012) (opens in a new tab)
  90. Fazel et al. (2009) (opens in a new tab)
  91. FDA 510(k) K254038 (2026) (opens in a new tab)
  92. FDA clozapine REMS removal communication (2025) (opens in a new tab)
  93. FDA COBENFY approval announcement (2024) (opens in a new tab)
  94. FDA Global Substance Registration System (opens in a new tab)
  95. Feldman et al. (2014) (opens in a new tab)
  96. Finnerty et al. (2024) (opens in a new tab)
  97. Fioravanti et al. (2012) (opens in a new tab)
  98. Fitch et al. (2014) (opens in a new tab)
  99. Fochtmann et al. (2020) (opens in a new tab)
  100. Folsom et al. (2005) (opens in a new tab)
  101. Furukawa et al. (2015) (opens in a new tab)
  102. Furukawa et al. (2026) (opens in a new tab)
  103. Fusar-Poli et al. (2012) (opens in a new tab)
  104. Fusar-Poli et al. (2015) (opens in a new tab)
  105. Galderisi et al. (2018) (opens in a new tab)
  106. GBD 2019 Mental Disorders Collaborators (2022) (opens in a new tab)
  107. GDB 2021 Schizophrenia Collaborators (2026) (opens in a new tab)
  108. Gerlinger et al. (2013) (opens in a new tab)
  109. Gopalakrishnan et al. (2020) (opens in a new tab)
  110. Govil and Kantrowitz (2025) (opens in a new tab)
  111. Grattan et al. (2019) (opens in a new tab)
  112. Gupta et al. (2015) (opens in a new tab)
  113. Hany and Rizvi (2024) (opens in a new tab)
  114. Hartz et al. (2014) (opens in a new tab)
  115. Hawthorne et al. (2012) (opens in a new tab)
  116. Heinrichs and Zakzanis (1998) (opens in a new tab)
  117. Hermes et al. (2012) (opens in a new tab)
  118. Heslin and Weiss (2015) (opens in a new tab)
  119. Hilker et al. (2018) (opens in a new tab)
  120. Hixon et al. (2018) (opens in a new tab)
  121. Hjorthøj et al. (2017) (opens in a new tab)
  122. Hopkins et al. (2021) (opens in a new tab)
  123. Hor and Taylor (2010) (opens in a new tab)
  124. Howes and Kapur (2009) (opens in a new tab)
  125. Howes et al. (2012) (opens in a new tab)
  126. Howes et al. (2017) (opens in a new tab)
  127. Huhn et al. (2019) (opens in a new tab)
  128. Hunt et al. (2018) (opens in a new tab)
  129. Intra-Cellular Therapies CAPLYTA prescribing information (2023) (opens in a new tab)
  130. ISPOR (2025) (opens in a new tab)
  131. Jääskeläinen et al. (2013) (opens in a new tab)
  132. Johnsen et al. (2020) (opens in a new tab)
  133. Johnson & Johnson CAPLYTA relapse prevention approval announcement (2026) (opens in a new tab)
  134. Jones et al. (2006) (opens in a new tab)
  135. Jongsma et al. (2019) (opens in a new tab)
  136. Kadakia et al. (2022a) (opens in a new tab)
  137. Kadakia et al. (2022b) (opens in a new tab)
  138. Kahn et al. (2008) (opens in a new tab)
  139. Kahn et al. (2018) (opens in a new tab)
  140. Kamil and Velligan (2019) (opens in a new tab)
  141. Kane and Correll (2026) (opens in a new tab)
  142. Kane et al. (2015) (opens in a new tab)
  143. Kane et al. (2016) (opens in a new tab)
  144. Kane et al. (2020) (opens in a new tab)
  145. Kapur et al. (2000) (opens in a new tab)
  146. Kaul et al. (2024a) (opens in a new tab)
  147. Kaul et al. (2024b) (opens in a new tab)
  148. Kaul et al. (2024c) (opens in a new tab)
  149. Kaul et al. (2025) (opens in a new tab)
  150. Kay et al. (1987) (opens in a new tab)
  151. Keefe et al. (2025) (opens in a new tab)
  152. Keepers et al. (2020) (opens in a new tab)
  153. Kennedy et al. (2014) (opens in a new tab)
  154. Kessler et al. (2005) (opens in a new tab)
  155. Khaykin et al. (2010) (opens in a new tab)
  156. Kishimoto et al. (2019) (opens in a new tab)
  157. Kishimoto et al. (2021) (opens in a new tab)
  158. Korchia et al. (2023) (opens in a new tab)
  159. Krasa et al. (2025) (opens in a new tab)
  160. Krause et al. (2018) (opens in a new tab)
  161. Krystal et al. (2022) (opens in a new tab)
  162. Lacro et al. (2002) (opens in a new tab)
  163. Lafeuille et al. (2016) (opens in a new tab)
  164. Lally et al. (2016) (opens in a new tab)
  165. Lally et al. (2017) (opens in a new tab)
  166. LB Pharmaceuticals chief financial officer announcement (2026) (opens in a new tab)
  167. LB Pharmaceuticals corporate presentation (2026) (opens in a new tab)
  168. LB Pharmaceuticals expanded access policy (opens in a new tab)
  169. LB Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  170. LB Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  171. LB Pharmaceuticals Form S-1 (2025) (opens in a new tab)
  172. LB Pharmaceuticals ILLUMINATE-1 initiation announcement (2026) (opens in a new tab)
  173. LB Pharmaceuticals LB-102-001 clinical study report (2020) (opens in a new tab)
  174. LB Pharmaceuticals NOVA-1 protocol (2024) (opens in a new tab)
  175. LB Pharmaceuticals NOVA-1 statistical analysis plan (2024) (opens in a new tab)
  176. LB Pharmaceuticals NOVA-1 topline results announcement (2025) (opens in a new tab)
  177. LB Pharmaceuticals NOVA-2 initiation announcement (2026) (opens in a new tab)
  178. LB Pharmaceuticals NOVA-2 timing announcement (2026) (opens in a new tab)
  179. LB Pharmaceuticals phase 1 results announcement (2020) (opens in a new tab)
  180. LB Pharmaceuticals prospectus (2025) (opens in a new tab)
  181. LB Pharmaceuticals R&D Day announcement (2026) (opens in a new tab)
  182. LB Pharmaceuticals second quarter 2026 results announcement (2026) (opens in a new tab)
  183. Lenert et al. (2004) (opens in a new tab)
  184. Lerner et al. (2018) (opens in a new tab)
  185. Leucht et al. (2002) (opens in a new tab)
  186. Leucht et al. (2005) (opens in a new tab)
  187. Leucht et al. (2006) (opens in a new tab)
  188. Leucht et al. (2009) (opens in a new tab)
  189. Leucht et al. (2012) (opens in a new tab)
  190. Leucht et al. (2013) (opens in a new tab)
  191. Leucht et al. (2017) (opens in a new tab)
  192. Leucht et al. (2018) (opens in a new tab)
  193. Leucht et al. (2019) (opens in a new tab)
  194. Leucht et al. (2020) (opens in a new tab)
  195. Levitan et al. (2015) (opens in a new tab)
  196. Li et al. (2023) (opens in a new tab)
  197. Lieberman et al. (2005) (opens in a new tab)
  198. Lin et al. (2021) (opens in a new tab)
  199. Loebel et al. (2013) (opens in a new tab)
  200. Loebel et al. (2022) (opens in a new tab)
  201. Mahabaleshwarkar et al. (2021) (opens in a new tab)
  202. MapLight Therapeutics ZEPHYR topline results announcement (2026) (opens in a new tab)
  203. Maravic et al. (2025) (opens in a new tab)
  204. Marconi et al. (2016) (opens in a new tab)
  205. Marcus and Olfson (2008) (opens in a new tab)
  206. Marcus et al. (2017) (opens in a new tab)
  207. Marwaha and Johnson (2004) (opens in a new tab)
  208. McCutcheon et al. (2020a) (opens in a new tab)
  209. McCutcheon et al. (2020b) (opens in a new tab)
  210. McCutcheon et al. (2023) (opens in a new tab)
  211. McCutcheon et al. (2025) (opens in a new tab)
  212. McEvoy et al. (2005) (opens in a new tab)
  213. McGrath et al. (2004) (opens in a new tab)
  214. McGrath et al. (2008) (opens in a new tab)
  215. McKenna et al. (2024) (opens in a new tab)
  216. Melnick et al. (2025) (opens in a new tab)
  217. Merritt et al. (2016) (opens in a new tab)
  218. Mesholam-Gately et al. (2009) (opens in a new tab)
  219. Millier et al. (2014) (opens in a new tab)
  220. Milpharm amisulpride summary of product characteristics (2026) (opens in a new tab)
  221. Minerva Neurosciences (2026) (opens in a new tab)
  222. Mitchell et al. (2013) (opens in a new tab)
  223. Moghaddam and Javitt (2012) (opens in a new tab)
  224. Moreno-Küstner et al. (2018) (opens in a new tab)
  225. Napitupulu (2026) (opens in a new tab)
  226. Nasrallah et al. (2013) (opens in a new tab)
  227. NCQA 2027 Health Plan Ratings required measures (2026) (opens in a new tab)
  228. NCQA APM measure page (opens in a new tab)
  229. NCQA FUH measure page (opens in a new tab)
  230. NCQA FUM measure page (opens in a new tab)
  231. NCQA SAA measure page (opens in a new tab)
  232. NCQA SMC measure page (opens in a new tab)
  233. NCQA SMD measure page (opens in a new tab)
  234. NCQA SSD measure page (opens in a new tab)
  235. Neill et al. (2017) (opens in a new tab)
  236. Neurocrine Biosciences Form 10-K (2026) (opens in a new tab)
  237. Neurocrine Biosciences phase 2 results announcement (2024) (opens in a new tab)
  238. Neurocrine Biosciences phase 3 initiation announcement (2025) (opens in a new tab)
  239. Newron Pharmaceuticals ENIGMA-TRS 1 screening completion announcement (2026) (opens in a new tab)
  240. Newron Pharmaceuticals ENIGMA-TRS 2 update (2026) (opens in a new tab)
  241. Newron Pharmaceuticals study 008A topline results announcement (2024) (opens in a new tab)
  242. NICE (2014) (opens in a new tab)
  243. NICE technology appraisal project GID-TA11925 (2025) (opens in a new tab)
  244. NIMH (opens in a new tab)
  245. Obermeier et al. (2011) (opens in a new tab)
  246. Olfson et al. (2005) (opens in a new tab)
  247. Olfson et al. (2010) (opens in a new tab)
  248. Olfson et al. (2015) (opens in a new tab)
  249. Olfson et al. (2021) (opens in a new tab)
  250. Otsuka REXULTI prescribing information (2023) (opens in a new tab)
  251. Owens et al. (2019) (opens in a new tab)
  252. Palmer et al. (2005) (opens in a new tab)
  253. Patel et al. (2022) (opens in a new tab)
  254. Paul et al. (2022) (opens in a new tab)
  255. Pennington and McCrone (2017) (opens in a new tab)
  256. Penttilä et al. (2014) (opens in a new tab)
  257. Peuskens et al. (2014) (opens in a new tab)
  258. Pillinger et al. (2020) (opens in a new tab)
  259. Pilon et al. (2021a) (opens in a new tab)
  260. Pilon et al. (2021b) (opens in a new tab)
  261. Pompili et al. (2021) (opens in a new tab)
  262. Potkin et al. (2020) (opens in a new tab)
  263. Powers et al. (2020) (opens in a new tab)
  264. Prince et al. (2007) (opens in a new tab)
  265. Psych Congress (2024) (opens in a new tab)
  266. Radua et al. (2018) (opens in a new tab)
  267. Reviva Pharmaceuticals open-label extension results announcement (2025) (opens in a new tab)
  268. Reviva Pharmaceuticals RECOVER topline results announcement (2023) (opens in a new tab)
  269. Reviva Pharmaceuticals regulatory update (2025) (opens in a new tab)
  270. Reviva Pharmaceuticals second quarter results announcement (2026) (opens in a new tab)
  271. Ringeisen et al. (2023) (opens in a new tab)
  272. Ringeisen et al. (2025) (opens in a new tab)
  273. Roberts et al. (2018) (opens in a new tab)
  274. Robinson et al. (1999) (opens in a new tab)
  275. Rosenheck et al. (2006) (opens in a new tab)
  276. Roy et al. (2021) (opens in a new tab)
  277. Rubio et al. (2020) (opens in a new tab)
  278. Rutherford et al. (2014) (opens in a new tab)
  279. Sachs (2006) (opens in a new tab)
  280. Saha et al. (2005) (opens in a new tab)
  281. Salazar de Pablo et al. (2021) (opens in a new tab)
  282. Samara et al. (2015) (opens in a new tab)
  283. SAMHSA (2016) (opens in a new tab)
  284. San et al. (2016) (opens in a new tab)
  285. Sanofi Solian summary of product characteristics (2022) (opens in a new tab)
  286. Schneider-Thoma et al. (2022) (opens in a new tab)
  287. Schoemaker et al. (1997) (opens in a new tab)
  288. Seabury et al. (2014) (opens in a new tab)
  289. Selten et al. (2020) (opens in a new tab)
  290. Semahegn et al. (2020) (opens in a new tab)
  291. Simeone et al. (2015) (opens in a new tab)
  292. Simon et al. (2017) (opens in a new tab)
  293. Siskind et al. (2016) (opens in a new tab)
  294. Siskind et al. (2017) (opens in a new tab)
  295. Siskind et al. (2022) (opens in a new tab)
  296. Sokoloff and Le Foll (2017) (opens in a new tab)
  297. Solmi et al. (2022) (opens in a new tab)
  298. Solmi et al. (2023) (opens in a new tab)
  299. Soumerai et al. (2008) (opens in a new tab)
  300. Storosum et al. (2023a) (opens in a new tab)
  301. Storosum et al. (2023b) (opens in a new tab)
  302. Suetani et al. (2026) (opens in a new tab)
  303. Sullivan et al. (2003) (opens in a new tab)
  304. Sumitomo Pharma and Otsuka DIAMOND topline results announcement (2023) (opens in a new tab)
  305. Sun et al. (2007) (opens in a new tab)
  306. Sunovion LATUDA prescribing information (2019) (opens in a new tab)
  307. Swartz et al. (2007) (opens in a new tab)
  308. Taipale et al. (2020) (opens in a new tab)
  309. Tandon et al. (2020) (opens in a new tab)
  310. Taylor (2025) (opens in a new tab)
  311. Teva and Medincell NDA acceptance announcement (2026) (opens in a new tab)
  312. Teva SOLARIS post hoc data announcement (2026) (opens in a new tab)
  313. The Fly Piper Sandler initiation (2025) (opens in a new tab)
  314. The Fly Stifel initiation (2025) (opens in a new tab)
  315. Tice et al. (2024) (opens in a new tab)
  316. Tiihonen et al. (2017) (opens in a new tab)
  317. Tkacz et al. (2026) (opens in a new tab)
  318. Trubetskoy et al. (2022) (opens in a new tab)
  319. Tumolo (2024) (opens in a new tab)
  320. Vaccaro et al. (2026) (opens in a new tab)
  321. Vaino et al. (2019) (opens in a new tab)
  322. Vaino et al. (2020) (opens in a new tab)
  323. Vaino et al. (2021) (opens in a new tab)
  324. Vancampfort et al. (2015) (opens in a new tab)
  325. Vanda Pharmaceuticals BYSANTI approval announcement (2026) (opens in a new tab)
  326. Varese et al. (2012) (opens in a new tab)
  327. Vassos et al. (2012) (opens in a new tab)
  328. Velligan et al. (2019) (opens in a new tab)
  329. Velthorst et al. (2017) (opens in a new tab)
  330. Vogt et al. (2011) (opens in a new tab)
  331. Wani et al. (2019) (opens in a new tab)
  332. Weiden et al. (2004) (opens in a new tab)
  333. Weiss and Jiang (2021) (opens in a new tab)
  334. WHO (2026) (opens in a new tab)
  335. WHO Collaborating Centre for Drug Statistics Methodology (2026) (opens in a new tab)
  336. WHO ICD-11 (2025) (opens in a new tab)
  337. Wong et al. (2021) (opens in a new tab)
  338. Wong et al. (2024) (opens in a new tab)
  339. Wu et al. (2006) (opens in a new tab)
  340. Wu et al. (2023) (opens in a new tab)
  341. Yohn et al. (2022) (opens in a new tab)
  342. Zhang et al. (2018) (opens in a new tab)
  343. Zhu et al. (2017) (opens in a new tab)
  344. Zipursky et al. (2014) (opens in a new tab)
  345. ZYPREXA prescribing information (2026) (opens in a new tab)